{"schema_version":"secwatch.filing_event.v1","accession":"0001082554-26-000007","form_type":"8-K","ticker":"UTHR","cik":"0001082554","company_name":"UNITED THERAPEUTICS Corp","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.512055+00:00","generated_at":"2026-05-16T00:04:43.604656+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"United Therapeutics reports record $3.18B FY2025 revenue; EPS $27.86 diluted","bullets":["FY 2025 revenue hit record $3.18B (+11% YoY); net income $1.33B ($27.86 diluted EPS) vs $1.20B ($24.64) in 2024.","Q4 revenue $790.2M (+7%); net income $364.3M ($7.70 diluted EPS) vs $301.3M ($6.19).","Tyvaso DPI sales $1.29B (+25% YoY); total Tyvaso $1.88B (+16%).","Orenitram sales $496.9M (+14% YoY).","Repurchased $1.0B of stock in 2025; litigation accrual reduced to $3M from $71.1M in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001082554-26-000007","json":"https://secwatch.observer/filing/0001082554-26-000007.json","markdown":"https://secwatch.observer/filing/0001082554-26-000007.md","text":"https://secwatch.observer/filing/0001082554-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/0001082554-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1082554/000108255426000007/uthr-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:04:43.604656+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}